Oppenheimer raised the firm’s price target on Ligand (LGND) to $145 from $142 and keeps an Outperform rating on the shares following quarterly results. Ligand remains in early stages of executing their royalty strategy, and the firm expects continued execution across the portfolio, further supported by deal-making throughout 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharma’s Strong Q1 Performance and Strategic Moves Justify Buy Rating with $135 Price Target
- Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth
- Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings
- Positive Outlook for Ligand Pharma: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Ligand sees FY25 adjusted EPS $6.00-$6.25, consensus $6.11